menu search

PHIO / PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up

PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up
PHIO surges on the FDA clearance of investigational new drug application for its lead product, PH-762, for the treatment of skin carcinomas. Read More
Posted: May 17 2023, 12:47
Author Name: Zacks Investment Research
Views: 091996

PHIO News  

PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data

By Zacks Investment Research
October 12, 2023

PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data

Data from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibition for treating various cancer indications like more_horizontal

Why Is Phio Pharma (PHIO) Stock Down 35% Today?

By InvestorPlace
October 12, 2023

Why Is Phio Pharma (PHIO) Stock Down 35% Today?

Phio Pharma (NASDAQ: PHIO ) stock is pulling back on Thursday after the immuno-oncology therapeutics company's shares underwent a major rally yesterd more_horizontal

PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up

By Zacks Investment Research
May 17, 2023

PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up

PHIO surges on the FDA clearance of investigational new drug application for its lead product, PH-762, for the treatment of skin carcinomas. more_horizontal

Why Is PHIO Stock Down 20% Today?

By InvestorPlace
April 18, 2023

Why Is PHIO Stock Down 20% Today?

It's been a big day for investors in Phio Pharmaceuticals (NASDAQ: PHIO ), unfortunately on the downside. This afternoon, PHIO stock has declined ne more_horizontal

Phio Pharma Shares Shine After Positive PH-894 Preclinical Data At AACR Presentation

By Benzinga
April 8, 2022

Phio Pharma Shares Shine After Positive PH-894 Preclinical Data At AACR Presentation

Phio Pharmaceuticals Corp (NASDAQ: PHIO) has presented new preclinical data for PH-894, a self-delivering RNAi compound targeting the bromodomain-c more_horizontal


Search within

Pages Search Results: